Supernus Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
10-K: Supernus Pharmaceuticals Reports 2025 Net Loss Amidst Strategic Acquisitions and Generic Pressures
Supernus Pharmaceuticals reported a net loss of $38.6 million in 2025, driven by the Sage Therapeutics acquisition and increased expenses, despite growth in key product sales and new product launches.
NASDAQ
Supernus Pharmaceuticals announces positive financial results for 2024 and FDA approval of ONAPGO for Parkinson's disease, while navigating generic competition and pipeline developments.
NASDAQ
Supernus Pharmaceuticals' 2023 10-K filing details patent litigation, product updates, and financial performance, highlighting both challenges and progress in their CNS-focused business.